1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapy
1995
Hypopigmented variant of mycosis fungoides: Demography, histopathology, and treatment of seven cases
Lambroza E, Cohen S, Phelps R, Lebwohl M, Braverman I, DiCostanzo D. Hypopigmented variant of mycosis fungoides: Demography, histopathology, and treatment of seven cases. Journal Of The American Academy Of Dermatology 1995, 32: 987-993. PMID: 7751470, DOI: 10.1016/0190-9622(95)91337-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack PeopleFemaleHumansHypopigmentationMaleMycosis FungoidesPUVA TherapySkinSkin NeoplasmsConceptsMycosis fungoidesEpidermal atrophyVariant of MFTreatment of choiceMedian ageMononuclear cellsHistologic findingsBiopsy diagnosisComplete repigmentationDisease onsetTreatment outcomesMF variantDisease processNew casesYoung populationPrior reportsFungoidesPUVAPatientsAtrophyMicroscopic featuresHistopathologyTreatmentDark skinSkinMalignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. JAMA Dermatology 1995, 131: 432-5. PMID: 7726585, DOI: 10.1001/archderm.131.4.432.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapy